inhaled interferon in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
2.45 [0.21 ; 28.37 ] Pandit, 2021, Shashi Bhushan, 2021 2 0% 289 moderate not evaluable deathsdetailed results Li, 2021 1.04 [0.02; 53.73]
Pandit, 2021 0.95 [0.02; 50.33]
Shashi Bhushan, 2021 4.39 [0.20; 98.33]
Synairgen SG016, 2020 0.16 [0.01; 3.31]
0.87 [0.16 ; 4.83 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 4 0% 484 moderate not evaluable clinical deteriorationdetailed results Li, 2021 0.52 [0.02; 15.78]
Synairgen SG016, 2020 0.50 [0.18; 1.38]
0.50 [0.19 ; 1.33 ] Li, 2021, Synairgen SG016, 2020 2 0% 195 moderate not evaluable clinical improvementdetailed results Li, 2021 1.76 [1.10; 2.81]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
Synairgen SG016, 2020 2.32 [1.07; 5.04]
1.64 [0.98 ; 2.76 ] Li, 2021, Shashi Bhushan, 2021, Synairgen SG016, 2020 3 33% 338 moderate not evaluable clinical improvement (14-day)detailed results Li, 2021 2.86 [1.24; 6.62]
Pandit, 2021 8.77 [0.94; 81.67]
Shashi Bhushan, 2021 0.68 [0.21; 2.20]
2.11 [0.60 ; 7.41 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 65% 375 moderate not evaluable clinical improvement (28-day)detailed results Li, 2021 4.26 [1.10; 16.44]
Synairgen SG016, 2020 3.15 [1.39; 7.14]
3.42 [1.70 ; 6.88 ] Li, 2021, Synairgen SG016, 2020 2 0% 195 moderate not evaluable clinical improvement (7-day)detailed results Li, 2021 1.83 [0.41; 8.14]
Shashi Bhushan, 2021 1.91 [1.03; 3.53]
1.90 [1.07 ; 3.35 ] Li, 2021, Shashi Bhushan, 2021 2 0% 316 moderate not evaluable clinical improvement (time to event analysis only)detailed results Li, 2021 1.76 [1.10; 2.81]
1.76 [1.10 ; 2.81 ] Li, 2021 1 0% 96 NA not evaluable death or ventilationdetailed results Synairgen SG016, 2020 0.38 [0.09; 1.63]
0.38 [0.09 ; 1.63 ] Synairgen SG016, 2020 1 0% NA not evaluable hospital dischargedetailed results Synairgen SG016, 2020 1.63 [0.61; 4.35]
1.63 [0.61 ; 4.35 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable mechanical ventilationdetailed results Li, 2021 0.52 [0.02; 15.78]
0.52 [0.02 ; 15.78 ] Li, 2021 1 0% 94 NA not evaluable viral clearance detailed results Li, 2021 7.68 [0.91; 65.15]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.90 [1.64 ; 5.14 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 0% 375 moderate not evaluable viral clearance (time to event analysis only)detailed results Li, 2021 1.74 [1.10; 2.75]
1.74 [1.10 ; 2.75 ] Li, 2021 1 0% 96 NA not evaluable viral clearance by day 14detailed results Li, 2021 1.74 [0.71; 4.29]
Pandit, 2021 10.23 [1.12; 93.35]
Shashi Bhushan, 2021 0.00 [0.00; 0.01]
0.38 [0.00 ; 46.74 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 98% 1,453 moderate not evaluable viral clearance by day 7detailed results Li, 2021 2.20 [0.95; 5.10]
Pandit, 2021 2.33 [0.55; 9.83]
Shashi Bhushan, 2021 2.77 [1.44; 5.32]
2.52 [1.55 ; 4.09 ] Li, 2021, Pandit, 2021, Shashi Bhushan, 2021 3 0% 375 moderate not evaluable recoverydetailed results Synairgen SG016, 2020 2.19 [1.03; 4.67]
2.19 [1.03 ; 4.67 ] Synairgen SG016, 2020 1 0% 101 NA not evaluable serious adverse eventsdetailed results Pandit, 2021 0.95 [0.02; 50.33]
0.95 [0.02 ; 50.33 ] Pandit, 2021 1 0% 39 NA not evaluable adverse eventsdetailed results Pandit, 2021 1.68 [0.47; 5.97]
1.68 [0.47 ; 5.97 ] Pandit, 2021 1 0% 39 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-06 07:29 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 896,899,1235,898,687
- roots T: 290
